Clinical Trial Update: Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL [Phase 2, Phase 3]

View source ↗

Summary

The trial studying dasatinib in imatinib-resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome‑positive acute lymphoblastic leukemia has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: WITHDRAWN